# PepGen Inc.: overview PEPG · Nasdaq · CIK 1835597 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pepg.md) · [Financials](/companies/pepg/financials.md) · [Filings](/companies/pepg/filings.md) · [Insiders](/companies/pepg/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.66)](/filings/0001193125-25-276001.md) | not reported | [(0.92)](/filings/0001193125-26-219375.md) | [(0.70)](/filings/0001193125-26-336754.md) | [(0.52)](/filings/0001193125-25-276001.md) | not reported | [(0.26)](/filings/0001193125-26-219375.md) | [(0.26)](/filings/0001193125-26-336754.md) | | Free cash flow | $m | [(24.2) d](/filings/0001193125-25-276001.md) | [(19.7) d](/filings/0001193125-26-091536.md) | [(23.1)](/filings/0001193125-26-219375.md) | [(23.6) d](/filings/0001193125-26-336754.md) | [(19.4) d](/filings/0001193125-25-276001.md) | [(15.8) d](/filings/0001193125-26-091536.md) | [(18.4)](/filings/0001193125-26-219375.md) | [(15.8) d](/filings/0001193125-26-336754.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(30.27)](/filings/0000950170-23-009500.md) | [(4.42)](/filings/0000950170-24-038417.md) | [(3.30)](/filings/0000950170-25-025226.md) | [(2.85)](/filings/0001193125-26-091536.md) | [(2.12)](/filings/0001193125-26-091536.md) | | Free cash flow | $m | [(23.1)](/filings/0000950170-23-009500.md) | [(63.0)](/filings/0000950170-24-038417.md) | [(71.6)](/filings/0000950170-25-025226.md) | [(82.9)](/filings/0001193125-26-091536.md) | [(81.9)](/filings/0001193125-26-091536.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pepg/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $36.1m | 20,064,545 | | Unchanged | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $8.1m | 4,475,000 | | Unchanged | | [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $6.3m | 3,482,434 | | Unchanged | | [Laurion Capital Management LP](/funds/1390202.md) | 2026-06-30 | $5.0m | 2,750,855 | | Unchanged | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $4.7m | 2,591,085 | | Added +983,447 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $4.2m | 2,325,000 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.5m | 1,935,920 | | Reduced −1,779 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $3.2m | 1,786,765 | | Reduced −292,378 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.7m | 1,520,246 | | Added +1,463,446 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.3m | 1,304,262 | | Added +26,478 | ## Recent filings [All 304 filings](/companies/pepg/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 07:40 ET | [8-K](/filings/0001193125-26-336767.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-336767 | | 2026-08-06 | 07:30 ET | [10-Q](/filings/0001193125-26-336754.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336754 | | 2026-06-22 | 16:30 ET | [8-K](/filings/0001193125-26-277579.md) | 5.07 Shareholder vote results | 0001193125-26-277579 | | 2026-05-21 | 07:30 ET | [8-K](/filings/0001193125-26-233403.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-233403 | | 2026-05-12 | 16:10 ET | [8-K](/filings/0001193125-26-219424.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219424 | | 2026-05-12 | 16:05 ET | [10-Q](/filings/0001193125-26-219375.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219375 | | 2026-04-28 | 16:05 ET | [DEF 14A](/filings/0001193125-26-186927.md) | Proxy statement, period 2026-06-18 | 0001193125-26-186927 | | 2026-03-30 | 17:30 ET | [8-K](/filings/0001193125-26-131786.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-131786 | | 2026-03-04 | 17:02 ET | [8-K](/filings/0001193125-26-091784.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-091784 | | 2026-03-04 | 16:15 ET | [10-K](/filings/0001193125-26-091536.md) | Annual report, period 2025-12-31 | 0001193125-26-091536 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-091536.md), filed Mar 4, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1835597 - Tickers: PEPG - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.